Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Captopril-Induced Eruption: A Possible Mechanism: Cutaneous Kinin Potentiation

The Captopril-Induced Eruption: A Possible Mechanism: Cutaneous Kinin Potentiation Abstract • Captopril, an orally active dipeptidylcarboxypeptidase inhibitor, is a promising new antihypertensive agent. Cutaneous reactions are the most common side effects of this therapy. The data from 15 previous cases and seven new ones are reviewed. The cutaneous eruptions appear to be pharmacologic in nature, occurring mostly at higher dosage schedules and resolving at lower dosage levels. Historical data, the results of skin tests, and the known pharmacology of captopril suggest that these captopril-induced eruptions may be the result of potentiation of kinin-mediated cutaneous reactions. (Arch Dermatol 116:902-905, 1980) References 1. Ondetti MA, Rubin B, Cushman DW: Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents . Science 196:441-444, 1977.Crossref 2. Ferguson RK, Turini GA, Brunner HR, et al: A specific orally active inhibitor of angiotensinconverting enzyme in man . Lancet 1:775-778, 1977.Crossref 3. Brunner HR, Waeber B, Wauters J-P, et al: Inappropriate renin secretion unmasked by captopril (SQ14,225) in hypertension of chronic renal failure . Lancet 2:704-707, 1978.Crossref 4. Gavras H, Brunner HR, Turini GA, et al: Antihypertensive effect of the oral angiotensinconverting enzyme inhibitor SQ14,225 in man . N Engl J Med 298:991-995, 1978.Crossref 5. Research Investigator's Brochure (SQ14,225): Clinical Pharmacology of SQ14,225: Interim Phase I Summary . Princeton, NJ, The Squibb Institute for Medical Research, 1978, pp 1-12. 6. Case DB, Atlas SA, Laragh JH, et al: Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral convertingenzyme inhibitor (SQ14,225 captopril) in hypertensive patients . Prog Cardiovasc Dis 21:195-206, 1978.Crossref 7. Bravo EL, Tarazi RC: Converting enzyme inhibition with an orally active compound in hypertensive man . Hypertension 1:39-46, 1979.Crossref 8. McGiff JC, Nasjletti A: Kinins, renal function and blood pressure regulation . Fed Proc 35:172-174, 1976. 9. Nasjletti A, Colina-Chourio J: Interaction of mineralocorticoids, renal prostaglandins and the renal kallikrein-kinin system . Fed Proc 35:189-193, 1976. 10. Nasjletti A, Colina-Chourio J, McGiff JC: Effect of kininase inhibition on canine renal blood flow and sodium excretion . Acta Physiol Lat Am 24:587-591, 1974. 11. Williams GH, Hollenberg NK: Accentuated vascular and endocrine response to SQ20,881 in hypertension . N Engl J Med 297:184-188, 1977.Crossref 12. Berova N, Petkov I, Andreev VC: Treatment of chronic urticaria with a proteinase (kallikrein) inhibitor . Br J Dermatol 90:431-434, 1974.Crossref 13. Chapman LF, Goodell H, Wolff HG: Increased inflammatory reaction induced by central nervous system activity . Trans Assoc Am Physicians 72:84-110, 1959. 14. DeLaus FV, Winkelmann RK: Kinins in cold urticaria . Arch Dermatol 98:67-74,1968.Crossref 15. Michel B, Russell T, Winkelmann RK, et al: Release of kinins from site of wheal-and-flare allergic skin reactions . Int Arch Allergy Appl Immunol 39:616-624, 1970.Crossref 16. Chapman LF: Mechanisms of the flare reaction in human skin . J Invest Dermatol 69:88-97, 1977.Crossref 17. Winkelmann RK: Molecular inflammation of the skin . J Invest Dermatol 57:197-208, 1971.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

The Captopril-Induced Eruption: A Possible Mechanism: Cutaneous Kinin Potentiation

Loading next page...
 
/lp/american-medical-association/the-captopril-induced-eruption-a-possible-mechanism-cutaneous-kinin-kS6NbFFj2A

References (17)

Publisher
American Medical Association
Copyright
Copyright © 1980 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1980.01640320052013
Publisher site
See Article on Publisher Site

Abstract

Abstract • Captopril, an orally active dipeptidylcarboxypeptidase inhibitor, is a promising new antihypertensive agent. Cutaneous reactions are the most common side effects of this therapy. The data from 15 previous cases and seven new ones are reviewed. The cutaneous eruptions appear to be pharmacologic in nature, occurring mostly at higher dosage schedules and resolving at lower dosage levels. Historical data, the results of skin tests, and the known pharmacology of captopril suggest that these captopril-induced eruptions may be the result of potentiation of kinin-mediated cutaneous reactions. (Arch Dermatol 116:902-905, 1980) References 1. Ondetti MA, Rubin B, Cushman DW: Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents . Science 196:441-444, 1977.Crossref 2. Ferguson RK, Turini GA, Brunner HR, et al: A specific orally active inhibitor of angiotensinconverting enzyme in man . Lancet 1:775-778, 1977.Crossref 3. Brunner HR, Waeber B, Wauters J-P, et al: Inappropriate renin secretion unmasked by captopril (SQ14,225) in hypertension of chronic renal failure . Lancet 2:704-707, 1978.Crossref 4. Gavras H, Brunner HR, Turini GA, et al: Antihypertensive effect of the oral angiotensinconverting enzyme inhibitor SQ14,225 in man . N Engl J Med 298:991-995, 1978.Crossref 5. Research Investigator's Brochure (SQ14,225): Clinical Pharmacology of SQ14,225: Interim Phase I Summary . Princeton, NJ, The Squibb Institute for Medical Research, 1978, pp 1-12. 6. Case DB, Atlas SA, Laragh JH, et al: Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral convertingenzyme inhibitor (SQ14,225 captopril) in hypertensive patients . Prog Cardiovasc Dis 21:195-206, 1978.Crossref 7. Bravo EL, Tarazi RC: Converting enzyme inhibition with an orally active compound in hypertensive man . Hypertension 1:39-46, 1979.Crossref 8. McGiff JC, Nasjletti A: Kinins, renal function and blood pressure regulation . Fed Proc 35:172-174, 1976. 9. Nasjletti A, Colina-Chourio J: Interaction of mineralocorticoids, renal prostaglandins and the renal kallikrein-kinin system . Fed Proc 35:189-193, 1976. 10. Nasjletti A, Colina-Chourio J, McGiff JC: Effect of kininase inhibition on canine renal blood flow and sodium excretion . Acta Physiol Lat Am 24:587-591, 1974. 11. Williams GH, Hollenberg NK: Accentuated vascular and endocrine response to SQ20,881 in hypertension . N Engl J Med 297:184-188, 1977.Crossref 12. Berova N, Petkov I, Andreev VC: Treatment of chronic urticaria with a proteinase (kallikrein) inhibitor . Br J Dermatol 90:431-434, 1974.Crossref 13. Chapman LF, Goodell H, Wolff HG: Increased inflammatory reaction induced by central nervous system activity . Trans Assoc Am Physicians 72:84-110, 1959. 14. DeLaus FV, Winkelmann RK: Kinins in cold urticaria . Arch Dermatol 98:67-74,1968.Crossref 15. Michel B, Russell T, Winkelmann RK, et al: Release of kinins from site of wheal-and-flare allergic skin reactions . Int Arch Allergy Appl Immunol 39:616-624, 1970.Crossref 16. Chapman LF: Mechanisms of the flare reaction in human skin . J Invest Dermatol 69:88-97, 1977.Crossref 17. Winkelmann RK: Molecular inflammation of the skin . J Invest Dermatol 57:197-208, 1971.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: Aug 1, 1980

There are no references for this article.